Skip to content

ADMA Biologics ADMA Payments Of Debt Issuance Cost

Payments Of Debt Issuance Cost at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$4.95M
Tidewater logo
TidewaterTDW
$101K-98.0%
V2X logo
V2XVVX
$0-100%
HNI logo
HNIHNI
$3.65M
Virtu Financial logo
Virtu FinancialVIRT
$0-100%
HWK
HawkinsHWKN
$764K

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept adma:PaymentsOfDebtIssuanceCost.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's payments of debt issuance cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's payments of debt issuance cost?
ADMA Biologics (ADMA) reported payments of debt issuance cost of $559.25K in Q4 2025.
What does payments of debt issuance cost mean?
Direct cash expenditures, such as legal, accounting, and underwriting fees, incurred to issue new debt. These costs are capitalized and amortized over the life of the debt, and tracking them provides visibility into the cost of capital acquisition.